Share Performance

Stock Quote & Chart

Stock Quote | Stock Chart | Investment Calculator | Historical Lookup
Recent Newsmore >
09/28/17
Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will showcase data at ID Week 2017 taking place from October 4-8 in San Diego, California. At the meeting, three presentations will feature the company’s m... 
09/20/17
Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Chief Executive Officer Colin Broom, M.D., will provide a company overview, including the previously released lefamulin evaluation against pneumonia (LEAP 1) Phase 3 trial topline results, a... 
09/19/17
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,411,764 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of t...